股價及成交量不尋常波動 信達生物(01801.HK)澄清:業務運營一切正常 有信心帶動公司價值持續提升
格隆匯1月5日丨信達生物(01801.HK)公吿稱,公司關注到股份近期股價及成交量出現不正常波動,公司特此澄清,公司業務運營一切正常,對公司發展充滿信心。在中國欣欣向榮的創新藥發展浪潮中,公司堅定做好做強國內市場,堅定推進全球創新研發,加速從生物科技公司(biotech)向全球生物製藥公司(global biopharma)的轉型,帶動公司持續發展。
至今,公司已建立一條擁有26個臨牀不同階段產品的管線,以及超過80個臨牀前立項項目。
公司已擁有6款獲批產品。其中達伯舒®(信迪例單抗注射液)自上市以來,持續保持快速的銷量及銷售額增長,更新增三項大適應症納入2022年新版國家醫保目錄,成為醫保覆蓋人羣最廣的PD1抑制劑品牌。公司有信心2022年保持達伯舒®(信迪例單抗注射液)的市場領先地位和持續的銷量及銷售額增長。公司亦將持續擴大其它獲批產品的銷售量及銷售規模,專業化商業團隊能力持續提升。
此外,公司預計未來2年內至少擴充至十款以上獲批產品,公司有信心有能力保持業務運營的長期穩健增長。公司已建立起六萬升的規模化抗體生產產能,確保滿足產品的充足供應和生產成本優勢。
除PD-1外,公司亦全面加速推進諸多具有開發全球性價值的管線,如CD47、LAG-3、PDL1/CD47、TIGIT、KRAS及臨牀階段的多款產品。在公司的全球性管線中,看到令人鼓舞的安全性和療效性資料,公司將在近期的專業會議上予以報吿。
公司強調,其將繼續做好現有的六款已經上市的產品在國內的推廣工作,並堅定的推進全球創新研發的步伐,打造高價值的全球產品鏈,有信心帶動公司價值的持續提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.